CATX - AMEX
Perspective Therapeutics, Inc.
$3.56
-1.1%Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
At a Glance
Live SnapshotPerspective Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Outstanding operational efficiency. The company generates substantial profit from core operations.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Interest or tax burden: Strong operational performance but thin net margins indicate high interest expenses or unfavorable tax position eating into profits.
Perspective Therapeutics, Inc. Income Statement
CATX • AMEX
| Perspective Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | Jun 2008 | Jun 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
884K | 0.0 | 1.4M | 7.1M | 10.8M | 10.1M | 9.7M | 7.3M | 5.9M | 4.8M | 4.8M | 4.6M | 4.2M | 4.5M | 5.1M | 5.2M | 5.3M | 5.4M | 7.2M | 5.7M | |
GROSS PROFIT | ||||||||||||||||||||
(3.3M) | (0.0) | (0.0) | (5.5M) | (6.2M) | (4.9M) | (4.6M) | (4.3M) | (4.1M) | (3.9M) | (4.6M) | (4.4M) | (4.4M) | (4.4M) | (4.4M) | (4.1M) | (4.6M) | (5.8M) | (7.3M) | (5.8M) | |
-2.4M | 0.0 | 1.4M | 1.6M | 4.6M | 5.1M | 5.1M | 3M | 1.8M | 838K | 129.2K | 167.4K | -196.5K | 150.2K | 703.2K | 1.2M | 725.8K | -353.3K | -151.4K | -54.6K | |
OPERATING INCOME | ||||||||||||||||||||
(101.2M) | (92.3M) | (42.4M) | (17.4M) | (12M) | (8.6M) | (8.6M) | (8.3M) | (8.6M) | (7.1M) | (5.2M) | (4.5M) | (4.4M) | (4.2M) | (4.3M) | (4.1M) | (4.7M) | (6.1M) | (8.7M) | (9.6M) | |
(30.2M) | (26.6M) | (21.1M) | (14.2M) | (9.4M) | (7.1M) | (7.5M) | (6.9M) | (6.8M) | (6.2M) | (5.1M) | (3.9M) | (3.7M) | (3.6M) | (3.6M) | (3.7M) | (4.4M) | (5.2M) | (7.3M) | (8.3M) | |
(84.2M) | (41.6M) | (21.3M) | (2.6M) | (2.6M) | (1.4M) | (1.1M) | (1.5M) | (1.7M) | (965K) | (528K) | (614.8K) | (668.8K) | (627.1K) | (730.6K) | (465.3K) | (341K) | (958.7K) | (1.4M) | (1.3M) | |
9.1M | 10.5M | -40.9M | -15.2M | -7.4M | -3.4M | -3.5M | -5.3M | -6.7M | -6.3M | -5.1M | -4.3M | -4.6M | -4.1M | -3.6M | -3M | -4M | -6.5M | -8.8M | -9.7M | |
PRE-TAX INCOME | ||||||||||||||||||||
-376K | -48K | (84K) | (0.0) | (119K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (1K) | (2K) | (883.0) | (7.0) | (61.7K) | (216.6K) | (36.4K) | (75.3K) | (274K) | (0.0) | |
7.7M | 10.6M | 850K | 1.1M | 0.0 | 59K | 30K | 108K | 29K | 118K | 217K | 281K | 11.2K | 657.0 | -60.9K | -213.2K | -25K | 35.7K | -274K | 0.0 | |
-13.3M | (24.1M) | (0.0) | (0.0) | (0.0) | (0.0) | -73K | (2K) | (0.0) | -48K | -456.3K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-113.1M | -91.8M | 835K | 512K | 119K | 50K | 30K | 134K | 29K | 27K | 154K | 374.6K | -1.4M | 210K | 170K | 334K | 0.0 | 274K | -274K | 0.0 | |
-103.9M | -81.4M | -40.1M | -14.7M | -7.3M | -3.4M | -3.4M | -5.1M | -6.7M | -6.2M | -4.7M | -3.7M | -6M | -3.9M | -3.4M | -2.8M | 0.0 | -6.2M | -9.1M | 0.0 | |
NET INCOME | ||||||||||||||||||||
-793K | -2.1M | -2.7M | (0.0) | -119K | -199K | -177K | -294K | -29K | -145K | -371.2K | -655.1K | (1.4M) | -210.7K | -109.1K | -120.8K | (25K) | -309.7K | -245.2K | -94.7K | |
-103.1M | -79.3M | -46.5M | -14.7M | -7.2M | -3.2M | -3.3M | -4.9M | -6.7M | -6.2M | -4.7M | -3.7M | -6M | -3.9M | -3.5M | -2.8M | -4M | -6.2M | -8.6M | -9.6M |
SEC Filings
CATX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 01, 2026 | June 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 27, 2026 | May 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 22, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 20, 2026 | April 18, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 16, 2026 | April 15, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 01, 2026 | April 01, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 16, 2026 | December 31, 2025 | 2025 |
Related Guides
Continue your CATX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.